{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T11:27:23Z","timestamp":1765279643722},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2008,6,10]],"date-time":"2008-06-10T00:00:00Z","timestamp":1213056000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2008,7]]},"DOI":"10.1038\/sj.bjc.6604421","type":"journal-article","created":{"date-parts":[[2008,6,10]],"date-time":"2008-06-10T07:58:35Z","timestamp":1213084715000},"page":"44-50","source":"Crossref","is-referenced-by-count":47,"title":["Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma"],"prefix":"10.1038","volume":"99","author":[{"given":"J B","family":"S\u00f8rensen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Frank","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Palshof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,6,10]]},"reference":[{"key":"BF6604421_CR1","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1093\/annonc\/mdh356","volume":"15","author":"E Andreopoulou","year":"2004","unstructured":"Andreopoulou E, Ross PJ, O'Brien MER, Ford HER, Priest K, Eisen T, Norton A, Aschley S, Smith IE (2004) The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma. Ann of Oncol 15: 1406\u20131412","journal-title":"Ann of Oncol"},{"key":"BF6604421_CR2","first-page":"75","volume":"50","author":"T Berghmans","year":"2005","unstructured":"Berghmans T, Lafitte JJ, Paesmans M, Stach B, Berchier MC, Wackenier P, Lecomte J, Collon T, Mommen P, Sculier JP (2005) A phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesothelioma. Cancer 50: 75\u201382. DOI 10.1016\/j.lungcan.2005.05.007","journal-title":"Cancer"},{"key":"BF6604421_CR3","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/S0169-5002(02)00180-0","volume":"38","author":"T Berghmans","year":"2002","unstructured":"Berghmans T, Paesmans M, Lalami Y, Louviaux I, Luce S, Mascaux C, Meert AP, Schulier JP (2002) Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with metaanalysis. Lung cancer 38: 111\u2013121","journal-title":"Lung cancer"},{"key":"BF6604421_CR4","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1200\/JCO.2005.03.3027","volume":"24","author":"A Bottomley","year":"2006","unstructured":"Bottomley A, Gaafa R, Manegold C, Burgers S, Coens C, Legrand C, Vincent M, Giaccone G, Van Meerbeeck J (2006) Short-term treatment related symptoms and quality of life: Results from an international randomized phase III study of Cisplatin with or without raltitrexed in patients with malignant pleural Mesothelioma: An EORTC lung-cancer group and National Cancer Institute, Canada, intergroup study. J Clin Oncol 24: 1435\u20131442","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"BF6604421_CR5","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1016\/S0169-5002(03)91714-4","volume":"41","author":"MJ Boyer","year":"2003","unstructured":"Boyer MJ, Jassem J, Liepa AM (2003) Symptom and quality of life advantages for pemetrexed+Cisplatin versus Cisplatin alone in treatment of malignant pleural Mesothelioma. Lung Cancer 41 (Suppl 2): S19","journal-title":"Lung Cancer"},{"key":"BF6604421_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1200\/JCO.1999.17.1.25","volume":"17","author":"MJ Byrne","year":"1999","unstructured":"Byrne MJ, Davidson JA, Musk AW, Dewar J, van Hazel G, Buck M, de Klerk NH, Robinson BWS (1999) Cisplatin and gemcitabine treatment for malignant pleural mesothelioma: a phase II study. J Clin Oncol 17: 25\u201330","journal-title":"J Clin Oncol"},{"key":"BF6604421_CR7","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/annonc\/mdh059","volume":"15","author":"MJ Byrne","year":"2004","unstructured":"Byrne MJ, Nowak AK (2004) Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 15: 257\u2013260","journal-title":"Ann Oncol"},{"key":"BF6604421_CR8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/annonc\/mdj912","volume":"17","author":"GL Ceresoli","year":"2006","unstructured":"Ceresoli GL, Betta GP, Castagneto B, Facciolo F, Arcangeli G, Zucali PA, Libener R, De Giovanni D, Melis E, Mirri MA (2006a) Malignant pleural mesothelioma. Ann of Oncol 17: 13\u201316","journal-title":"Ann of Oncol"},{"key":"BF6604421_CR9","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.ctrv.2007.07.012","volume":"33","author":"GL Ceresoli","year":"2007","unstructured":"Ceresoli GL, Chiti A, Zucali PA, Cappuzzo F, de Vincenzo F, Cavina R, Rodari M, Poretti D, Lutman FR, Santoro A (2007) Assessment of tumor response in malignant pleural mesothelioma. Can Treat Rev 33: 533\u2013541","journal-title":"Can Treat Rev"},{"key":"BF6604421_CR10","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1200\/JCO.2005.04.3190","volume":"24","author":"GL Ceresoli","year":"2006","unstructured":"Ceresoli GL, Zucali PA, Favaretto AG, Grossi F, Bidoli P, Del Conte G, Ceribelli A, Bearz A, Morenghi E, Cavina R, Marangolo M, Soto HJ, Santoro A (2006b) Phase II study of Pemetrexed plus Carboplatin in Malignant Pleural Mesothelioma. J Clin Oncol 24: 1443\u20131448. DOI: 10.1200\/JCO.2005.04.3190","journal-title":"J Clin Oncol"},{"key":"BF6604421_CR11","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1200\/JCO.1998.16.1.145","volume":"16","author":"D Curran","year":"1998","unstructured":"Curran D, Sahmoud T, Theressa P, van Meerbeeck J, Postmus PE, Giaccone G (1998) Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer Experience. J Clin Oncol 16: 145\u2013152","journal-title":"J Clin Oncol"},{"key":"BF6604421_CR12","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1097\/01243894-200607000-00017","volume":"1","author":"P Ellis","year":"2006","unstructured":"Ellis P, Davies AM, Evans WK, Haynes AE, Lloyd NS (2006) The use of chemotherapy in patients with advanced malignant Pleural Mesothelioma: a systematic review and practice guideline. J Thorac Oncol 1: 591\u2013601","journal-title":"J Thorac Oncol"},{"key":"BF6604421_CR13","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1002\/cncr.11405","volume":"97","author":"AG Favaretto","year":"2003","unstructured":"Favaretto AG, Aversa SM, Paccagnella A, Manzini VDP, Palmisano V, Oniga F, Stefani M, Rea F, Bortolotti L, Loreggian L, Monfardini S (2003) Gemcitabine combined with Carboplatin in patients with Malignant Pleural Mesothelioma. A multicentric phase II study. Cancer 97: 2791\u20132797. DOI 10.1002\/cncr.11405","journal-title":"Cancer"},{"key":"BF6604421_CR14","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/0021-9681(61)90060-1","volume":"13","author":"EA Gehan","year":"1961","unstructured":"Gehan EA (1961) The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis 13: 346\u2013353","journal-title":"J Chronic Dis"},{"key":"BF6604421_CR15","first-page":"1","volume":"1","author":"J Green","year":"2007","unstructured":"Green J, Dundar Y, Dodd S, Dickson R, Walley T (2007) Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma (Review). Cochrane Database Syst Rev 1: 1\u201315. DOI:10.1002\/14651858","journal-title":"Cochrane Database Syst Rev"},{"key":"BF6604421_CR16","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1378\/chest.113.3.723","volume":"113","author":"JE Herndon","year":"1998","unstructured":"Herndon JE, Green MR, Chahinian AP, Corson JM, Suzuki Y, Vogelzang NJ (1998) Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 113: 723\u2013731","journal-title":"Chest"},{"key":"BF6604421_CR17","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1200\/JCO.1994.12.2.360","volume":"12","author":"T LeChevalier","year":"1994","unstructured":"LeChevalier T, Brisgand D, Douillard JY, Pujol JL, Alberola V, Monnier A, Riviere A, Lianes P, Chomy P, Cigolari S (1994) Randomized study of Navelbine and cisplatin versus vindesine and cisplatin versus navelbine alone in advanced non-small-cell lung cancer. Results of a European multicenter trial including 612 patients. J Clin Oncol 12: 360\u2013367","journal-title":"J Clin Oncol"},{"key":"BF6604421_CR18","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.lungcan.2003.07.005","volume":"43","author":"F Monetti","year":"2004","unstructured":"Monetti F, Casanova S, Grasso A, Cafferata MA, Ardizzoni A, Neumaier CE (2004) Inadequacy of the new Response evaluation Criteria in Solid Tumors (RECIST) in patients with malignant pleural mesothelioma: report of four cases. Lung Cancer 43: 71\u201374. DOI:10.1016\/j.lungcan.2003.07.005","journal-title":"Lung Cancer"},{"issue":"18S","key":"BF6604421_CR19","first-page":"390s","volume":"25","author":"M Muers","year":"2007","unstructured":"Muers M, Fisher P, Snee M, Lowry E, O'Brien M, Peake M, Rudd R, Nankivell M, Pugh C, Stephens RJ (2007) A randomized phase III trial of active symptom control (ASC) with or without chemotherapy in the treatment of patients with malignant pleural Mesothelioma: First results of the British Thoracic Society (BTS)\/Medical Research Ccouncil (MRC) MS01 trial. J Clin Oncol 25 (18S): 390s, abstract 7525","journal-title":"J Clin Oncol"},{"key":"BF6604421_CR20","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.lungcan.2006.09.023","volume":"55","author":"CK Obasaju","year":"2007","unstructured":"Obasaju CK, Ye Z, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, Mintzer DM, Monberg MJ, J\u00e4nne PA (2007) Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naive patients with malignant pleural mesothelioma: outcomes of an expanded access program. Lung Cancer 55: 187\u2013194. DOI:10.1016\/j.lungcan.2006.09.023","journal-title":"Lung Cancer"},{"key":"BF6604421_CR21","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1378\/chest.108.4.1122","volume":"108","author":"VW Rusch","year":"1995","unstructured":"Rusch VW (1995) A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 108: 1122\u20131128","journal-title":"Chest"},{"issue":"18S","key":"BF6604421_CR22","first-page":"424s","volume":"25","author":"A Santoro","year":"2007","unstructured":"Santoro A, O'Brien S, Stahel R, Nackaerts K, Baas P, Paz-Ares L, Sundstr\u00f8m S, Visseren-Grut C, Blatter J, Manegold C (2007) Pemetrexed plus cisplatin (P+Cis) or pemetrexed plus carboplatin (P+Cb) for chemonaive patients (pts) with malignant (MPM): Results of the International Expanded Access Program (EAP). J Clin Oncol 25 (18S): 424s, abstr. 7662","journal-title":"J Clin Oncol"},{"key":"BF6604421_CR23","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1200\/JCO.2003.06.122","volume":"21","author":"GV Scagliotti","year":"2003","unstructured":"Scagliotti GV, Shin DM, Kindler HL, Vasconcelles MJ, Keppler U, Manegold C, Burris H, Gatzemeier U, Blatter J, Symanowski JT, Rusthoven JJ (2003) Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 21: 1556\u20131561","journal-title":"J Clin Oncol"},{"key":"BF6604421_CR24","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/j.1752-699X.2008.00046.x","volume":"2","author":"JB S\u00f8rensen","year":"2008","unstructured":"S\u00f8rensen JB (2008) Current concepts in chemotherapy for malignant pleural Mesothelioma. Clin Respir J 2: 74\u201379","journal-title":"Clin Respir J"},{"key":"BF6604421_CR25","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1200\/JCO.2000.18.23.3912","volume":"18","author":"JPC Steele","year":"2000","unstructured":"Steele JPC, Shamash J, Evans MT, Gower NH, Tischkowitz MD, Rudd RM (2000) Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 18: 3912\u20133917","journal-title":"J Clin Oncol"},{"key":"BF6604421_CR26","doi-asserted-by":"publisher","first-page":"S103","DOI":"10.1016\/j.lungcan.2004.04.020","volume":"455","author":"S Tomek","year":"2004","unstructured":"Tomek S, Manegold C (2004) Chemotherapy for malignant pleural mesothelioma: past results and recent developments. Lung Cancer 455: S103\u2013S119","journal-title":"Lung Cancer"},{"key":"BF6604421_CR27","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/S0140-6736(04)17108-0","volume":"364","author":"T Treasure","year":"2004","unstructured":"Treasure T, Sedrakyan A (2004) Pleural mesothelioma: little evidence, still time to do trials. Lancet 364: 1183\u20131185","journal-title":"Lancet"},{"key":"BF6604421_CR28","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/sj.bjc.6600118","volume":"86","author":"JMW van Haarst","year":"2002","unstructured":"van Haarst JMW, Baas P, Manegold C, Schouwink JH, Burgers JA, de Bruin HG, Mooi WJ, van Klaveren RJ, de Jonge MJ, van Meerbeeck JP (2002) Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer 86: 342\u2013345","journal-title":"Br J Cancer"},{"key":"BF6604421_CR29","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0169-5002(03)00292-7","volume":"43","author":"RJ van Klaveren","year":"2004","unstructured":"van Klaveren RJ, Aerts JGJV, de Bruin H, Giaccone G, Manegold C, van Meerbeeck JP (2004) Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma. Lung Cancer 43: 63\u201369. DOI:10.1016\/50169-5002(03)00292-7","journal-title":"Lung Cancer"},{"key":"BF6604421_CR30","doi-asserted-by":"publisher","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","volume":"23","author":"JP van Meerbeeck","year":"2005","unstructured":"van Meerbeeck JP, Gaafar R, Manegold C, van Klaveren RJ, van Marck EA, Vincent M, Legrand C, Bottomley A, Debruyne C, Giaccone G (2005) Randomized Phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma. An intergroup study of the EORTC Lung Cancer Group and the NCIC. J Clin Oncol 23: 6881\u20136889. DOI 10.1200\/jco.2005.14.589","journal-title":"J Clin Oncol"},{"key":"BF6604421_CR31","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1053\/sonc.2002.37469","volume":"29","author":"NJ Vogelzang","year":"2002","unstructured":"Vogelzang NJ (2002) Emerging insights into the biology and therapy of malignant mesothelioma. Seminars of Oncology 29: 35\u201342","journal-title":"Seminars of Oncology"},{"key":"BF6604421_CR32","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21: 2636\u20132644","journal-title":"J Clin Oncol"},{"key":"BF6604421_CR33","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1200\/JCO.1998.16.7.2459","volume":"16","author":"AJ Wozniak","year":"1998","unstructured":"Wozniak AJ, Crowley JJ, Balcerzak SP, Weiss GR, Spiridonidis CH, Baker LH, Albain KS, Kelly K, Taylor SA, Gandara DR, Livingston RB (1998) Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study. J Clin Oncol 16: 2459\u20132465","journal-title":"J Clin Oncol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6604421.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6604421","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6604421.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:33:32Z","timestamp":1684413212000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6604421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6,10]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["BF6604421"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6604421","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,6,10]]}}}